{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:36:29Z","timestamp":1761060989083,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ahj.2019.12.024","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T21:21:32Z","timestamp":1582838492000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial"],"prefix":"10.1016","volume":"223","author":[{"given":"Robert J.","family":"Mentz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudaye","family":"Tasissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Heitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana L.","family":"Pi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Lala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Lanfear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahazarin","family":"Ginwalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Old","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S.","family":"Salacata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.12.024_bb0005","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ahj.2019.12.024_bb0015","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0020","unstructured":"US Food and Drug Administration. Ivabradine (Corlanor) label. Accessed at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206143orig1s000lbl.pdf on February 8, 2019."},{"key":"10.1016\/j.ahj.2019.12.024_bb0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.ahj.2019.12.024_bb0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","article-title":"Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)","volume":"12","author":"Swedberg","year":"2010","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0045","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0055","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ahj.2019.12.024_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines-Heart Failure (GWTG-HF)","volume":"5","author":"Luo","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005400","article-title":"Patient, provider, and practice characteristics associated with sacubitril\/valsartan use in the United States","volume":"11","author":"DeVore","year":"2018","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jchf.2013.01.008","article-title":"Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients","volume":"1","author":"Eapen","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ahj.2019.12.024_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchf.2015.09.002","article-title":"Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION Trial","volume":"4","author":"Fiuzat","year":"2016","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ahj.2019.12.024_bb0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0095","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2017.03.563","article-title":"Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement?","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0100","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.amjcard.2008.07.045","article-title":"Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)","volume":"102","author":"Fonarow","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.recesp.2016.11.039","article-title":"Effects of ivabradine on heart rate and hemodynamic parameters in a swine model of cardiogenic shock","volume":"70","author":"Pascual Izco","year":"2017","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0110","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","article-title":"Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients","volume":"62","author":"Reil","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.12.024_bb0115","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032030065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:04:25Z","timestamp":1757570665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287032030065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"alternative-id":["S000287032030065X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.12.024","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}